Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $45.7143.

Several equities research analysts recently commented on the company. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Morgan Stanley lifted their price target on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Guggenheim reissued a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a report on Friday, August 14th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th.

Zenas BioPharma Stock Performance

Shares of ZBIO opened at $31.27 on Friday. The business’s fifty day simple moving average is $29.62 and its two-hundred day simple moving average is $24.21. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -3.48 and a beta of -1.03.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. Research analysts anticipate that Zenas BioPharma will post -5.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zenas BioPharma

A number of large investors have recently made changes to their positions in ZBIO. Vanguard Group Inc. increased its holdings in Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the last quarter. Walleye Capital LLC bought a new position in Zenas BioPharma in the 2nd quarter worth $5,306,000. NEXTBio Capital Management LP bought a new position in shares of Zenas BioPharma in the fourth quarter worth about $11,691,000. Bank of America Corp DE raised its stake in Zenas BioPharma by 723.5% during the 1st quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock worth $7,592,000 after acquiring an additional 341,187 shares during the period. Finally, EcoR1 Capital LLC purchased a new position in shares of Zenas BioPharma during the 4th quarter valued at $28,667,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.